Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...
The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...
The Brighterside of News on MSN1h
Weight-loss drug Semaglutide could significantly reduce the risk of heart attacksA new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...
For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...
The weight-loss jab Wegovy has been hailed as an “absolute game-changer” after a new study showed that it relieved symptoms ...
Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, ...
2d
Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic ...
Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...
Heart failure during pregnancy is a dangerous and often under-detected condition because common symptoms-shortness of breath, ...
The medication, finerenone, could be an effective therapy in people with heart failure who have mildly reduced or preserved ejection fraction, suggests the study, published Sunday in the New Engla ...
Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and ...
[21] This was a smaller study that enrolled 74 patients 65 years and older with NYHA class II or III heart failure (defined by the Framingham criteria) and an ejection fraction ≥40%. Background ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback